Menu
← Oncology Approval Tracker
FDA DECISION ·
Danyelza + GM-CSF
naxitamab-gqgk + granulocyte-macrophage colony-stimulating factor · Y-mAbs Therapeutics
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Adults and children ages one year and older with relapsed or refractory high-risk neuroblastoma in bone or bone marrow who had a partial response, minor response or stable disease with prior therapy.
LAMPGEN ANALYSIS
Why it matters
Added an anti-GD2 antibody combination for a narrowly defined high-risk neuroblastoma population under accelerated approval.
What research teams should watch
Capture the prior response category and plan infusion pain management and blood-pressure monitoring.
PRIMARY RECORDS